AI-driven Biomarkers
Assessing GLP-1’s Cardioprotective Benefits with an ECG-based AI-Biomarker
Here, we collaborated with DandelionHealth, a real-world data (RWD) provider, to extract valuable information from multi-omic patient data collected in real-world clinical settings.
One key application of our AI-biomarkers is in enhancing the evidence generated from RCTs and real-world observational studies. Here we validated and applied one of our AI-biomarkers, an algorithm predicting cardiovascular risk from 12-lead ECGs in collaboration with Dandelion Health. Using our AI-Biomarker we find that GLP-1s could benefit a much broader population than initially tested in the SELECT trial and could prevent ~34K strokes and MIs annually.
.svg)
.svg)
